Texas THC Law Changes: Legal Status, Delta-8, and Medical Cannabis Updates

Executive Summary

Texas enacted significant changes to its THC laws in August 2026, expanding the state's limited medical cannabis program and adjusting hemp-derived THC regulations that affect neighboring states including Oklahoma. The modifications represent the most substantial shift in Texas cannabis policy since the 2019 expansion of the Compassionate Use Program. While Texas remains one of the most restrictive states for cannabis access, the new framework increases qualifying conditions for low-THC medical cannabis, adjusts possession thresholds for criminal penalties, and clarifies the legal status of hemp-derived cannabinoids including delta-8 THC and THCA. The changes have immediate implications for approximately 60,000 registered patients in the Texas Compassionate Use Program, an estimated 2.4 million Texans who could now qualify for medical access, and cross-border patients from Oklahoma and other states who previously purchased hemp products in Texas. The regulatory shift also impacts the state's 73 licensed dispensing organizations and the broader $500 million Texas hemp industry.

Why This Matters

Texas THC law changes affect the nation's second-largest state by population and economy, creating ripple effects across the South-Central cannabis market and establishing precedent for conservative-leaning states considering reform. With 30 million residents, Texas represents the largest untapped adult-use cannabis market in the United States, and even incremental medical program expansion significantly impacts patient access and industry development. The stakeholder impact spans multiple dimensions. For patients, the expanded qualifying conditions under the Compassionate Use Program provide legal access to approximately 2.4 million Texans with conditions including chronic pain, PTSD, and anxiety disorders who previously had no legal cannabis options. The Texas Department of Public Safety estimates this represents a tenfold increase from the current 60,000 registered patients. For the 73 licensed dispensing organizations operating under the Compassionate Use Registry, the expansion creates substantial revenue opportunities in a market previously capped by restrictive qualifying conditions. Cross-border implications are equally significant. Oklahoma, which operates one of the nation's most permissive medical cannabis programs with over 376,000 licensed patients, has seen substantial Texas resident participation. An estimated 15-20% of Oklahoma medical cannabis purchases come from out-of-state patients, with Texans representing the largest contingent. The Texas law changes affect these cross-border dynamics, particularly regarding hemp-derived products that Oklahoma patients previously purchased in Texas due to more favorable pricing or product availability. The economic scale is substantial. The Texas hemp industry generated an estimated $500 million in 2025 sales, with hemp-derived THC products representing approximately 60% of that total. The Compassionate Use Program, despite its restrictive nature, generated $89 million in 2025 sales. Industry analysts project the expanded medical program could reach $400-600 million in annual sales by 2028, creating 3,000-5,000 direct jobs and generating $30-50 million in annual state tax revenue.

Background and History

Texas cannabis policy has evolved through incremental legislative reforms over eight years, moving from one of the nation's most restrictive frameworks to a limited medical program with ongoing expansion.

The Compassionate Use Act (2015)

The Texas Legislature passed the Compassionate Use Act in 2015 as House Bill 892, establishing the nation's most restrictive medical cannabis program. The law, codified in Texas Health and Safety Code Chapter 169, permitted only low-THC cannabis oil containing no more than 0.5% THC by weight for patients with intractable epilepsy. The program required physician prescription rather than recommendation, mandated registration with the Department of Public Safety Compassionate Use Registry, and limited the number of licensed dispensing organizations to three statewide. The 2015 framework reflected the political reality of cannabis reform in Texas, where conservative legislative leadership opposed broader legalization but responded to compelling testimony from parents of children with severe epilepsy. The Compassionate Use Act passed the Texas House 96-34 and the Senate 26-5, representing rare bipartisan agreement on cannabis policy.

2019 Expansion: House Bill 3703

The 86th Texas Legislature expanded the Compassionate Use Program through House Bill 3703, signed by Governor Greg Abbott in June 2019. The legislation increased the THC cap from 0.5% to 1.0% by weight, expanded qualifying conditions to include terminal cancer, multiple sclerosis, spasticity, amyotrophic lateral sclerosis, autism, and seizure disorders beyond just intractable epilepsy, and increased the number of licensed dispensing organizations from three to twelve. House Bill 3703 also shifted the physician requirement from "prescription" to "recommendation," aligning Texas more closely with other medical cannabis states and reducing physician liability concerns. The expansion took effect September 1, 2019, and resulted in patient enrollment increasing from approximately 1,400 in 2018 to 8,000 by the end of 2019.

Hemp Legalization and Delta-8 THC Emergence (2019-2023)

The 2018 federal Agriculture Improvement Act legalized hemp containing no more than 0.3% delta-9 THC by dry weight, prompting Texas to align state law through House Bill 1325 in 2019. The legislation, codified in Texas Agriculture Code Chapter 122, legalized hemp cultivation, processing, and sales, and explicitly removed hemp from the Texas Controlled Substances Act definition of marijuana. The hemp legalization created an unintended regulatory gap that allowed hemp-derived delta-8 THC products to proliferate across Texas. Delta-8 THC, a psychoactive cannabinoid that occurs naturally in hemp in trace amounts but can be synthesized from CBD, became widely available in gas stations, smoke shops, and online retailers. By 2022, the Texas hemp-derived THC market reached an estimated $300 million in annual sales. The Texas Department of State Health Services attempted to ban delta-8 THC in October 2021 by adding it to the state's controlled substances schedule, but a Travis County district court issued a temporary injunction blocking the ban in February 2022. The case, Hometown Hero CBD v. Texas Department of State Health Services, established that delta-8 THC derived from legal hemp fell within the statutory definition of legal hemp products under House Bill 1325.

2021 Medical Program Expansion: House Bill 1535

The 87th Texas Legislature further expanded the Compassionate Use Program through House Bill 1535, signed in June 2021. The legislation added chronic pain, post-traumatic stress disorder, and all forms of cancer to the qualifying conditions list, increased the THC cap to 5.0% by weight, and expanded the number of licensed dispensing organizations to 73 statewide. House Bill 1535 represented the most significant expansion of Texas medical cannabis access to date, with chronic pain and PTSD qualifying conditions potentially covering millions of Texans. The law took effect September 1, 2021, and patient enrollment accelerated rapidly, reaching 60,000 registered patients by December 2025.

Decriminalization Efforts and Local Reforms (2019-2025)

While statewide legalization efforts stalled in the Texas Legislature, several cities enacted local decriminalization measures. Austin passed a resolution in January 2020 directing police to deprioritize low-level marijuana possession arrests. Dallas County District Attorney John Creuzot announced in April 2019 that his office would not prosecute first-time marijuana possession cases involving less than four ounces. Similar prosecutorial discretion policies were adopted in Harris County, Travis County, and Bexar County. The Texas House passed House Bill 441 in April 2021, which would have reduced penalties for possession of one ounce or less of marijuana from a Class B misdemeanor to a Class C misdemeanor punishable only by fine. The bill died in the Senate Criminal Justice Committee, reflecting continued resistance to broader decriminalization among conservative Senate leadership.

The 2026 Legislative Session and August Reforms

The 89th Texas Legislature convened in January 2026 with cannabis reform as a prominent agenda item. House Bill 2796 and Senate Bill 589, companion bills filed in February 2026, proposed expanding Compassionate Use Program qualifying conditions to include anxiety disorders, depression, insomnia, and any condition for which a physician believes cannabis could provide therapeutic benefit. The legislation also proposed increasing licensed dispensing organizations to 150 statewide and establishing a regulatory framework for hemp-derived THC products. After extensive committee hearings and amendments, the Legislature passed a compromise version in May 2026. Governor Abbott signed the legislation on June 15, 2026, with an effective date of August 1, 2026. The reforms represented the culmination of eight years of incremental expansion and addressed both medical cannabis access and hemp-derived cannabinoid regulation.

Key Players

Texas Department of Public Safety

The Texas Department of Public Safety administers the Compassionate Use Registry, which tracks all registered patients, physicians, and dispensing organizations. The agency processes patient applications, conducts background checks on dispensing organization employees, and enforces compliance with program regulations. Under the 2026 reforms, DPS received expanded authority to audit dispensing organizations and increased funding for registry system upgrades to handle anticipated patient enrollment growth.

Texas Department of State Health Services

The Texas Department of State Health Services regulates the medical aspects of the Compassionate Use Program, including establishing product testing standards, approving physician participation, and setting dosage guidelines. The agency also oversees public health education regarding medical cannabis use. Following the 2026 reforms, DSHS published updated product testing protocols requiring analysis for pesticides, heavy metals, microbial contaminants, and cannabinoid potency.

Texas Department of Agriculture

The Texas Department of Agriculture regulates hemp cultivation and processing under the state's hemp program established by House Bill 1325. The agency licenses hemp growers, conducts THC testing of hemp crops, and enforces compliance with the 0.3% delta-9 THC threshold. The 2026 reforms expanded TDA authority to regulate hemp-derived cannabinoid products, requiring product registration and testing for all hemp-derived THC products sold in Texas.

Licensed Dispensing Organizations

Texas currently licenses 73 dispensing organizations authorized to cultivate, process, and dispense low-THC cannabis to registered patients. Major operators include Compassionate Cultivation, Cansortium Texas, Goodblend Texas, and Texas Original Compassionate Cultivation. These vertically integrated operators invested an estimated $200-300 million in cultivation facilities, processing infrastructure, and retail locations. The 2026 reforms allow these organizations to expand product offerings and serve a significantly larger patient population.

Texas Cannabis Industry Association

The Texas Cannabis Industry Association represents licensed dispensing organizations, hemp businesses, and ancillary service providers. The organization lobbied extensively for the 2026 reforms, providing testimony during legislative hearings and coordinating industry input on regulatory implementation. TCIA estimates the reforms will create 5,000 new industry jobs by 2028.

Texans for Responsible Marijuana Policy

Texans for Responsible Marijuana Policy, a coalition of patient advocates, medical professionals, and reform organizations, advocated for expanded medical access and reduced criminal penalties. The organization mobilized patient testimony during the 2026 legislative session and conducted public education campaigns highlighting the therapeutic benefits of medical cannabis for PTSD, chronic pain, and anxiety disorders.

Opposition Groups

Conservative advocacy organizations including Texas Values and Empower Texans opposed the 2026 reforms, arguing that expanded medical cannabis access would lead to increased youth use and normalize recreational consumption. Law enforcement organizations including the Texas Municipal Police Association expressed concerns about impaired driving and workplace safety. These groups lobbied unsuccessfully to limit qualifying conditions and maintain stricter THC potency caps.

Legal and Regulatory Framework

The 2026 Texas THC law changes modify multiple statutory provisions across the Texas Health and Safety Code, Agriculture Code, and Penal Code, creating a complex regulatory framework for medical cannabis and hemp-derived products. The Compassionate Use Program operates under Texas Health and Safety Code Chapter 169, as amended by the 2026 legislation. The statute defines "low-THC cannabis" as cannabis containing no more than 5.0% THC by weight and at least 10% CBD by weight. The 2026 amendments removed the CBD minimum requirement for certain qualifying conditions, allowing dispensing organizations to offer higher-THC, lower-CBD products for chronic pain and PTSD patients. Qualifying conditions now include intractable epilepsy, seizure disorders, multiple sclerosis, spasticity, amyotrophic lateral sclerosis, autism, terminal cancer, all forms of cancer, chronic pain, post-traumatic stress disorder, anxiety disorders, major depressive disorder, insomnia, and any condition for which a physician believes cannabis could provide therapeutic benefit. The "physician discretion" provision represents the most significant expansion, effectively allowing any condition to qualify if a licensed physician provides written certification. Patient registration requires submission of an application to the Department of Public Safety Compassionate Use Registry, including physician certification, proof of Texas residency, and a $50 application fee. Patients receive a registry identification card valid for one year. Physicians must hold an active Texas medical license and complete a two-hour continuing medical education course on medical cannabis therapeutics before certifying patients. Possession limits allow registered patients to possess up to 16 ounces of low-THC cannabis in any form, including flower, concentrates, edibles, and topicals. The 2026 reforms added flower as an approved product form, reversing the previous restriction to oils, tinctures, and edibles only. Patients may designate one caregiver to purchase and possess medical cannabis on their behalf. Hemp regulation operates under Texas Agriculture Code Chapter 122, as amended by the 2026 legislation. The statute defines "hemp" as cannabis containing no more than 0.3% delta-9 THC by dry weight. The 2026 amendments added specific provisions for hemp-derived cannabinoids, defining "hemp-derived THC" as any THC isomer derived from legal hemp, including delta-8 THC, delta-10 THC, THC-O, and THCA. The amendments require all hemp-derived THC products to be tested by an accredited laboratory and registered with the Texas Department of Agriculture. Products must be labeled with total THC content, serving size, and a warning that the product is not approved by the FDA. The legislation prohibits hemp-derived THC products containing more than 10 mg of THC per serving or 100 mg per package for edibles, and requires child-resistant packaging. Criminal penalties under Texas Penal Code Chapter 481 remain unchanged for non-medical cannabis possession. Possession of less than two ounces remains a Class B misdemeanor punishable by up to 180 days in jail and a $2,000 fine. Possession of two to four ounces is a Class A misdemeanor, four ounces to five pounds is a state jail felony, and possession of more than five pounds is a third-degree felony. The 2026 legislation did not include decriminalization provisions, despite advocacy efforts. Federal law continues to classify cannabis as a Schedule I controlled substance under the Controlled Substances Act, 21 U.S.C. § 812. The conflict between state medical cannabis programs and federal prohibition creates ongoing legal uncertainty, particularly regarding banking access, interstate commerce, and federal prosecution risk. The Rohrabacher-Farr Amendment, renewed annually in federal appropriations bills, prohibits the Department of Justice from using funds to prevent states from implementing medical cannabis laws, providing limited protection for state-compliant programs.

State-by-State Breakdown of Regional Impact

The Texas THC law changes affect cross-border dynamics with neighboring states, particularly Oklahoma, Louisiana, New Mexico, and Arkansas, each of which operates distinct cannabis regulatory frameworks.

Oklahoma

Oklahoma operates one of the nation's most permissive medical cannabis programs, with over 376,000 licensed patients and 2,100 licensed dispensaries as of July 2026. The state allows medical cannabis for any condition with physician recommendation, imposes no possession limits for registered patients, and permits home cultivation of up to six mature plants. Oklahoma's program has attracted substantial out-of-state patient participation, with an estimated 15-20% of purchases coming from Texas residents who obtained Oklahoma medical cards. The Texas law changes affect this cross-border dynamic in two ways. First, expanded Texas qualifying conditions reduce the incentive for Texas residents to obtain Oklahoma medical cards, potentially decreasing Oklahoma dispensary revenue from Texas patients. Second, Texas hemp-derived THC regulations create product standardization that may influence Oklahoma hemp market practices, particularly regarding potency limits and testing requirements.

Louisiana

Louisiana operates a limited medical cannabis program similar to the pre-2026 Texas framework. The state permits medical cannabis for 20 specific qualifying conditions, limits cultivation to two licensed growers, and restricts product forms to oils, tinctures, and edibles. Louisiana does not permit flower sales. The state's program served approximately 15,000 registered patients as of July 2026, with chronic pain and PTSD representing the most common qualifying conditions. The Texas expansion creates competitive pressure on Louisiana to liberalize its program. Louisiana patients near the Texas border may seek to establish Texas residency or utilize Texas hemp-derived products if access proves easier than navigating Louisiana's restrictive medical program. Louisiana legislators have cited Texas reforms as justification for proposed program expansion in the 2027 legislative session.

New Mexico

New Mexico legalized adult-use cannabis in April 2021, with sales beginning in April 2022. The state allows adults 21 and older to possess up to two ounces of cannabis flower and 16 grams of concentrate, and permits home cultivation of up to six mature plants per person. New Mexico's adult-use market generated $318 million in sales in 2025, with approximately 8-10% of purchases coming from Texas residents crossing the border. The Texas medical expansion is unlikely to significantly impact New Mexico's adult-use market, as Texas medical patients still face more restrictive access than New Mexico adult consumers. However, Texas hemp-derived THC regulations may influence New Mexico's approach to hemp products, which currently exist in a regulatory gray area separate from the licensed adult-use market.

Arkansas

Arkansas operates a medical cannabis program serving approximately 85,000 registered patients as of July 2026. The state permits medical cannabis for 18 qualifying conditions, licenses 38 dispensaries statewide, and allows patients to possess up to 2.5 ounces every 14 days. Arkansas does not permit home cultivation. The state's program generated $263 million in sales in 2025. Arkansas and Texas medical programs now have similar qualifying condition lists and potency allowances, creating rough parity in medical access. The Texas expansion may reduce Arkansas dispensary revenue from Texas residents in border areas who previously obtained Arkansas medical cards. Arkansas voters will consider an adult-use legalization ballot measure in November 2026, which if approved would create a more significant policy divergence between the states.

Market and Business Implications

The Texas THC law changes create immediate revenue opportunities for licensed dispensing organizations, reshape the hemp-derived cannabinoid market, and position Texas as a potential bellwether for Southern cannabis policy. The expanded Compassionate Use Program represents a market expansion from 60,000 registered patients to a potential 2.4 million qualifying patients. Industry analysts project patient enrollment will reach 200,000-300,000 within the first year of implementation and 500,000-750,000 within three years. At an average annual patient spend of $800-1,200, the Texas medical cannabis market could reach $400-600 million in annual sales by 2028, compared to $89 million in 2025. Licensed dispensing organizations face significant capital requirements to scale operations for the expanded patient population. Cultivation capacity must increase substantially, with operators projecting a need for 500,000-750,000 square feet of additional canopy to meet demand. Processing infrastructure must expand to produce flower, concentrates, edibles, and topicals at scale. Retail footprint must grow from the current 73 dispensary locations to an estimated 150-200 locations to provide adequate patient access statewide. The 73 licensed dispensing organizations hold significant competitive advantages as incumbent operators with established cultivation, processing, and distribution infrastructure. The 2026 legislation does not authorize additional dispensing organization licenses until 2028, creating a protected oligopoly for current licensees. This market structure allows existing operators to capture the entire medical market expansion without new competition, driving substantial valuation increases for licensed entities. Multi-state operators with Texas licenses, including Trulieve (operating as Goodblend Texas), Curaleaf (operating as Compassionate Cultivation), and Green Thumb Industries (operating as Rise Texas), gain exposure to the nation's second-largest state market. These operators can leverage operational expertise from other state markets to scale Texas operations efficiently, creating competitive advantages over Texas-only operators. The hemp-derived THC market faces significant restructuring under the new regulatory framework. The requirement for product registration, laboratory testing, and potency limits increases compliance costs and eliminates low-quality products from the market. Industry analysts estimate 30-40% of current hemp-derived THC retailers will exit the market due to inability to meet compliance requirements. Compliant hemp operators gain market legitimacy and consumer trust through the regulatory framework. The establishment of testing standards, potency limits, and labeling requirements creates product differentiation between compliant and non-compliant offerings. Hemp operators that invest in compliance infrastructure position themselves for long-term market participation and potential acquisition by larger cannabis companies. The Texas reforms create precedent for other conservative-leaning states considering medical cannabis expansion. Texas's incremental approach—expanding qualifying conditions and potency limits while maintaining physician oversight and registry requirements—provides a political template for states including Tennessee, Kentucky, and South Carolina where full legalization faces legislative opposition. The Texas market's performance will influence policy debates in these states over the next 2-3 years. Capital markets respond positively to Texas medical expansion, with multi-state operators holding Texas licenses experiencing stock price increases of 8-15% in the week following the August 1 implementation. The Texas market expansion improves revenue projections and provides geographic diversification for operators concentrated in mature markets facing pricing compression. Debt and equity capital availability increases for Texas-licensed operators as lenders and investors gain confidence in market growth trajectory. Banking access remains constrained by federal cannabis prohibition under the Controlled Substances Act. Texas dispensing organizations continue to face challenges accessing traditional banking services, forcing reliance on credit unions, state-chartered banks, and cash operations. The SAFE Banking Act, which would protect financial institutions serving state-legal cannabis businesses, has not passed Congress as of August 2026, leaving banking uncertainty unresolved. Tax implications under Internal Revenue Code Section 280E continue to burden Texas dispensing organizations. Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses, resulting in effective tax rates of 60-80% of gross profit. Texas operators cannot deduct expenses including rent, salaries, marketing, and utilities, significantly reducing after-tax profitability. The federal tax burden limits capital available for expansion and reduces returns to investors.

What Experts Say

Industry analysts, medical professionals, patient advocates, and policy experts offer varied perspectives on the Texas THC law changes, with general consensus that the reforms represent meaningful progress within political constraints. According to Heather Fazio, director of Texans for Responsible Marijuana Policy, the 2026 reforms represent the most significant expansion of patient access in Texas history, with the physician discretion provision effectively creating a comprehensive medical cannabis program. Fazio noted that the reforms position Texas alongside states including Pennsylvania, Ohio, and Minnesota that allow medical cannabis for any condition with physician certification. Morris Denton, CEO of Compassionate Cultivation, stated that the company is investing $40 million in cultivation and processing expansion to meet anticipated demand from the expanded patient population. Denton projected that Compassionate Cultivation's patient count would increase from 8,000 to 50,000-75,000 within 18 months of implementation. Dr. Peter Grinspoon, a primary care physician and cannabis specialist at Massachusetts General Hospital, observed that the Texas reforms align with medical evidence supporting cannabis efficacy for chronic pain, PTSD, and anxiety disorders. Grinspoon noted that the 5.0% THC cap remains lower than optimal for some conditions, particularly severe chronic pain, but represents a significant improvement over the previous 1.0% limit. According to Jonathan Miller, general counsel for the U.S. Hemp Roundtable, the Texas hemp-derived THC regulations establish a reasonable framework balancing consumer access with product safety. Miller stated that the 10 mg per serving limit for edibles aligns with regulatory approaches in Colorado, California, and other adult-use states, and that testing requirements protect consumers from contaminated products. Paul Armentano, deputy director of NORML, characterized the Texas reforms as incremental progress that falls short of comprehensive legalization. Armentano noted that criminal penalties for non-medical possession remain unchanged, continuing to subject thousands of Texans to arrest and prosecution for cannabis possession. According to Texas Department of Public Safety data, law enforcement made 43,000 arrests for marijuana possession in 2025, with disproportionate impact on Black and Hispanic communities. Dr. Staci Gruber, director of the Marijuana Investigations for Neuroscientific Discovery program at McLean Hospital, emphasized the importance of product testing requirements in the hemp-derived THC regulations. Gruber stated that unregulated hemp products have shown high rates of contamination with pesticides, heavy metals, and inaccurate cannabinoid labeling, and that mandatory testing protects consumer health. According to Beau Whitney, senior economist at Whitney Economics, the Texas medical cannabis market could reach $800 million to $1.2 billion in annual sales by 2030 if patient enrollment reaches 1 million registered patients. Whitney projected that the market would create 8,000-12,000 direct jobs and generate $60-90 million in annual state tax revenue at maturity. Representative Stephanie Klick, author of House Bill 2796, stated that the legislation reflects a decade of advocacy by patients, families, and medical professionals who demonstrated the therapeutic value of medical cannabis. Klick noted that the reforms maintain appropriate physician oversight while expanding access to Texans suffering from debilitating conditions.

What's Next

Implementation of the Texas THC law changes will unfold over 12-18 months, with key regulatory deadlines, market developments, and potential legislative refinements shaping the program's evolution. The Texas Department of Public Safety began accepting patient applications under the expanded qualifying conditions on August 1, 2026. The agency projects processing 15,000-20,000 applications per month through the end of 2026, with patient enrollment reaching 150,000-200,000 by December 2026. DPS is implementing system upgrades to handle increased application volume and reduce processing times from the current 45-60 days to a target of 14-21 days. The Texas Department of Agriculture will begin accepting hemp-derived THC product registrations on September 1, 2026, with a compliance deadline of December 1, 2026. Products not registered by the deadline will be prohibited from sale in Texas. TDA estimates 5,000-7,000 product registrations will be submitted, requiring significant agency resources for review and approval. The agency is hiring 15 additional staff to manage the registration program. Licensed dispensing organizations are rapidly expanding cultivation and retail capacity. Trulieve announced plans to open 12 additional Texas dispensary locations by March 2027, bringing its total footprint to 25 locations statewide. Curaleaf is constructing a 100,000-square-foot cultivation expansion in Schulenburg, expected to be operational by January 2027. Industry sources indicate total capital investment by licensed operators will reach $150-200 million through 2027. Product availability will expand significantly through late 2026 and early 2027. Dispensing organizations are developing flower products, which were prohibited under previous regulations, with launches expected in September-October 2026. High-potency concentrates and edibles formulated for chronic pain patients will become available as cultivation capacity increases. Industry sources project product selection will triple from current offerings by the end of 2026. The Texas Legislature will reconvene in January 2027 for its regular biennial session. Cannabis reform advocates plan to introduce legislation addressing criminal penalties for non-medical possession, potentially reducing penalties for possession of less than one ounce to a civil citation with fine. Decriminalization efforts have failed in previous sessions but may gain traction given the expanded medical program and shifting public opinion. Ballot initiative efforts for adult-use legalization face significant obstacles in Texas. The state does not have a citizen initiative process, requiring all statutory changes to pass through the Legislature. Advocates are exploring a constitutional amendment strategy that would require two-thirds legislative approval and voter ratification, but this approach faces long odds in the conservative-controlled Legislature. Federal rescheduling of cannabis under the Controlled Substances Act remains uncertain. The Drug Enforcement Administration published a Notice of Proposed Rulemaking in May 2024 proposing to reschedule cannabis from Schedule I to Schedule III, which would eliminate Internal Revenue Code Section 280E tax penalties and reduce federal prosecution risk. The rulemaking process includes public comment, administrative law judge hearings, and final rule publication, with completion projected for late 2026 or early 2027. Rescheduling would significantly improve financial viability for Texas dispensing organizations. Interstate commerce in cannabis remains prohibited under federal law, limiting Texas operators to in-state cultivation and processing. If federal prohibition ends or Congress authorizes interstate commerce, Texas's large agricultural sector and favorable business climate could position the state as a major cannabis production hub for national distribution. However, this scenario remains speculative absent federal legislative action. Market consolidation among licensed dispensing organizations is likely over the next 2-3 years. The protected oligopoly structure and capital requirements for expansion create acquisition opportunities for well-funded operators. Industry analysts project 3-5 significant mergers or acquisitions among Texas dispensing organizations by 2028, with multi-state operators acquiring Texas-only operators to gain market share.

Further Reading

• Texas Health and Safety Code Chapter 169 (Compassionate Use Act) - Full statutory text at https://statutes.capitol.texas.gov/Docs/HS/htm/HS.169.htm
• Texas Agriculture Code Chapter 122 (Hemp Program) - Full statutory text at https://statutes.capitol.texas.gov/Docs/AG/htm/AG.122.htm
• Texas Department of Public Safety Compassionate Use Registry - Patient application portal and program information at https://www.dps.texas.gov/section/compassionate-use-registry-texas
• Texas Department of State Health Services Medical Cannabis Resources - Physician certification requirements and clinical guidelines at https://www.dshs.texas.gov/medical-cannabis
• Texas Department of Agriculture Hemp Program - Grower licensing and hemp-derived product registration at https://www.texasagriculture.gov/RegulatoryPrograms/Hemp.aspx
• House Bill 2796 (89th Legislature) - Full bill text and legislative history at https://capitol.texas.gov/BillLookup/History.aspx?LegSess=89R&Bill=HB2796
• Texans for Responsible Marijuana Policy - Patient advocacy resources and policy updates at https://www.texasmarijuanapolicy.org
• Texas Cannabis Industry Association - Industry data and business resources at https://www.texascannabis.org
• U.S. Hemp Roundtable - Federal and state hemp policy analysis at https://www.hempsupporter.com
• NORML Texas - Criminal justice reform advocacy and legal resources at https://norml.org/texas